Cardiovascular complications of polychemotherapy of oncohematological diseases: Modern approaches to diagnostics
DOI:
https://doi.org/10.14739/2310-1210.2012.6.18015Keywords:
cardiovascular events, polychemotherapy, diagnostics, prognostic factorsAbstract
Heart dysfunction that occurred after using of cytostatic drugs and monoclonal antibodies may be a limit factor in treatment of oncohematological diseases. Side effects of chemotherapy include decline of quality of life, hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis, thromboembolic events, heart failure, death. The risk of cardiotoxicity may be increased by some factors that include drug exposure, age, history of heart diseases, arterial hypertension, drug combination, previous radiotherapy or chemotherapy. It’s important to detect the cardiovascular toxicity before appearance of clinical signs of heart and vessel disturbance. The role of markers in elicitation of risk
group of cardiovascular events is uncertain yet. Early diagnostics and defi nition of prognostic factors of cardiovascular toxicity appeared after polychemotherapy of oncohematological diseases are important and not solved problems.
References
Abnormal beta-adrenergic transmembrane signaling in rabbits with adriamycin-induced cardiomyopathy / Nagami K., Yoshikawa T., Suzuki M. [et al.] // Jpn. Circ. J. – 1997. – Vol. 61. – P. 249–255.
Acute doxorubicin cardiotoxicity involves cardiomyocite apoptosis / Arola O.J., Saraste A., Pulkki K. [et al.] // Cancer Res. – 2000. – Vol. 60. – P. 1789–1792.
Adriamycin (NSC-123127) cardiomyopathy – an overview with determination of risk factors / Minow R.A., Benjamin R.S., Gottlieb J.A. // Cancer Chemother. Rep. – 1982. – Vol. 6. – P. 1757–1758.
Adriamycin cardiomyopathy risk factors / Benjamin R.S., Lee E.T., Gottlieb J.A. [et al.] // Cancer. – 1977. – Vol. 39. – P.1397–402.
Adriamycin cardiotoxicity: a survey of 1273 patients / Praga C., Beretta G., Vigo P.L. [et al.] // Cancer Treat. Rep. – 1979. – Vol. 63. – P. 827–834.
Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells / Sinha B.K., Katki A.G., Batist G. [et al.] // Biochem. Pharmacol. – 1987. – Vol. 36. – P. 793–796.
Alexander J. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography / Alexander J., Dainlak N., Berger H.J. // N. Engl. J. Med. 1979. – Vol. 300. – P. 430–435.
Al-Nasser I.A. In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506 / Al-Nasser I.A. // Toxicology. – 1998. –Vol. 131. – P. 175–181.
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity / Minotti G., Menna P., Salvatorelli E. [et al.] // Pharmacol. Rev. –2004. – Vol. 56 (2). – P. 185–229.
Appelbaum F. Acute lethal carditis caused by high-dose combination chemotherapy / Appelbaum F., Strauchen J.A., Graw Jr R.G. // A unique clinical and pathological entity. – Lancet. –1976. – Vol. 1. – P. 58–62.
Arico M. Severe and fatal anthracycline cardiotoxicity at doses below 400 mg/m2: evidence for enhanced toxicity with multiagent chemotherapy / Arico M., Pedroni E. // Am. J. Haematol. – 1991. – Vol. 36. – Vol. 217–278.
Assessment of left ventricular ejection fraction and volumes by real time two-dimensional echocardiography. A comparison of cineangiographic and radionucleotide techniques / Folland E.D., Parisi A.F., Moynihan P.F. [et al.] // Circulation. – 1979. – Vol. 60. – P. 760–766.
Balachandar A.V. Protective role of DLalpha-lipoic acid against adriamycin-induced cardiac lipid peroxidation / Balachandar A.V. Malarkodi K.P., Varalakshmi P. // Hum. Exp. Toxicol. – 2003. – Vol. 22. – Vol. 249–254.
Bhattacharya S. Clinical role of indium-111 antimyosin imaging/ Bhattacharya S., Lahiri A. // Eur. J. Nucl. Med. - 1991. – Vol. 18. – P. 889–895.
Cardiac changes with cyclophosphamide / Steinherz L.J., Steinherz P.G., Mangiacasale D. [et al.] // Med. Pediatr. Oncol. – 1981. –Vol. 9. – P. 417–422.
Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations / Cazin B., Gorin N.C., Laporte J.P. [et al.] // Cancer – 1986. – Vol. 57. – P. 2061–2069.
Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy fi ndings / Kupari M., Volin L., Suokas A. [et al.] // Bone Marrow Transplant. – 1990. – Vol. 5. – P. 91–98.
Cardiac side-effects of cancer chemotherapy / Monsuez J.J., Charniot J.C., Vignat N., Artigou J.Y. [et al.] // Int. J. Cardiol. – 2010. – Vol. 144(1). – P. 3–15.
Cardiac toxicity of high-dose chemotherapy / Morandi P., Ruffi ni P.A., Benvenuto G.M., Raimondi R. [et al.] // Bone Marrow Transplant. – 2005. – Vol. 35(4). – P. 323–334.
Cardiotoxicity 4 to 20 years after completing anthracycline therapy/ Steinhertz L.J., Steinhertz P.G., Tan C.T.C. [et al.] // JAMA. –1991. – Vol. 266. – P. 1672–1677.
Cardiotoxicity associated with high-dose cyclophosphamide therapy / Gottdiener J.S., Appelbaum F.R., Ferrans V.J. [et al.] //Arch. Intern. Med. – 1981. – Vol. 141. – P. 758–763.
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management / Yeh E.T., Tong A.T., Lenihan D. [et al.] // Circulation. – 2004. – Vol. 109. – P. 3122–3131.
Cardiovascular toxicity of the fi rst line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab / Drímal J, Zúrová Nedelcevová J, Knezl V. [et al.] // Neuro Endocrinol. Lett. – 2006. – Vol. 27, Suppl 2. – P. 176–179.
Cardotoxicity of chemotherapy / Castel M., Despas F., Modesto A. [et al.] // Presse Med. – 2012. – Vol. 6. – P. 21.
Clinical spectrum of anthracycline cardiotoxicity / Bristow M.R., Billingham M.E., Mason J.W. [et al.] // Cancer Treat. Rep. – 1978. – Vol. 62. – P. 873–879.
Comparative accuracy of apical biplane cross-sectional echocardiography and gated radionuclide angiography for estimating left ventricular size and performance / Starling M.R., Crawford M.H., Soresen S.G. [et al.] // Circulation. – 1981. – Vol. 63. – P. 1075–1083.
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience uses serial radionuclide angiocardiography / Schwartz R.G., McKenlie W.B., Alexander J. [et al.] // Am. J. Med. – 1987. – Vol. 82. – P. 1109.
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin / Herman E.H., Zhang J., Lipshultz S.E. [et al.] // J. Clin. Oncol.– 1999. – Vol. 17. – P. 2237–2243.
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens / Braverman A.C., Antin J.H., Plappert M.T. [et al.] // J. Clin. Oncol. – 1991. – Vol. 9. - P. 1215–1223.
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor / Goldberg M.A., Antin J.H., Guinan E.C. [et al.] // Blood. – 1986. – Vol. 68. – P. 1114–1118.
Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response / Ayash L.J., Wright J.E., Tretyakov O. [et al.] // J. Clin. Oncol. – 1992. – Vol. 10. – P. 995–1000.
Cyclophosphamide regimens in rhesus monkey with and without marrow infusion / Storb R., Buckner C.D., Dillingham L.A. [et al.] // Cancer Res. – 1970. – Vol. 30. – P. 2195–2203.
Damage is an early event in doxorubicin-induced cardiac myocyte death / L’Ecuyer T., Sanjeev S., Thomas R. [et al.] // Am. J. Physiol. Heart Circ. Physiol. – 2006. – Vol. 291(3). – P. H1273– H1280.
Daunomycin induced cardiotoxicity in children and adults: review of 110 cases / Von Hoff D.D., Rozencweig M., Layard M. [et al.] // Am. J. Med. – 1977. – Vol. 62. – P. 200–208.
Demonstration that adriamycin cardiotoxicity is mediated by vasoactive amines / Bristow M.R., Billingham M.E., Minobe W.A., [et al.] // J. Mol. Cell Cardiol. – 1979. – Vol. 2. – P. 10.
Dey H.M. Radionucleotide evaluation of doxorubicin cardiotoxicity. The need for cautious interpretation / Dey H.M., Kassmali H. // Clin. Nucl. Med. – 1988. – Vol. 13. – P. 565-568.
Di Marco A. Adriamycin (NSC-123 127): mode and mechanism of action / Di Marco A. // Cancer Chemother. Rep. – 1975/ - Vol. 6. – P. 91–106.
Doroshow J.H. Doxorubicin-induced cardiototoxicity / Doroshow J.H. // N. Engl. J. Med. – 1991. – Vol. 324. – P. 843–845.
Doroshow J.H. Enzymatic defences of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin / Doroshow J.H., Locker J.Y., Myers C.E. // J. Clin. Invest. 1980. – Vol. 65. – P. 128–135.
Earm Y.E. Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit / Earm Y.E., Ho W.K., So I. // J. Mol. Cell. Cardiol. – 1994. – Vol. 26. – P. 163–172.
Echocardiography in adriamycin cardiotoxicity / Bloom K., Bini R., Williams C. [et al.] // Cancer. – 1978. – Vol. 41. – P. 1265–1259.
Elevated B-type natriuretic peptide levels after anthracycline administration / Suzuki T., Hayashi D., Yamazaki T. [et al.] // Am. Heart J. – 2002. – Vol. 136. – P. 362– 363.
Epirubicin: clinical toxicity during the phase II program in endometrial and cervical cancer / Calero F., Jimeno J., Rodriguez-Escudero F. [et al.] // Eur. J. Gynaecol. Oncol. – 1992. – Vol. 13. – P. 83–89.
Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques / Meinardi M.T., van der Graaf W.T., Gietema J.A. [et al.] // Heart. – 2001. – Vol. 88. – P. 81–82.
Expression of nitric oxide synthase and aquaporin-3 in cyclophosphamide treated rat bladder / Cho K.H., Hyun J.H., Chang Y.S. // Int. Neurourol. J. – 2010. – Vol. 14. – P. 149–156.
Female sex and higher drug use as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer / Steven E., Lipshultz M.D., Stuart R. [et al.] // N. Engl. J. Med. – 1995. – Vol. 332. – P. 1738–1743.
Ferrero M.E. Adriamycin: energy metabolism and mitochondrial oxidations in the heart of treated rabbits /Ferrero M.E., Ferrero E., Gaja U. // Biochem. Pharmacol. – 1976. – Vol. 25. – P.125–130.
Ganz W.I. Review of tests for monitoring doxorubicin induced cardiomyopathy / Ganz W.I., Sridhar K.S. // Oncology. – 1996. – Vol. 53. – P. 461–470.
Grenier M.A. Epidemiology of anthracycline cardiotoxicity in children and adults / Grenier M.A., Lipshultz S.E. // Semin. Oncol. – 1998. – Vol. 25 (Suppl 10). – P. 72–85.
Hatch G.M. Regulation of cardiolipin biosynthesis in H9c2 cardiac myoblasts by cytidine 50-triphosphate / Hatch G.M., McClarty G. // J. Biol. Chem. – 1996. – Vol. 271. – P. 25810 25816.
Heart transplantation in patients with malignant disease / Armitage J.M., Kormos R.L., GriYth B.P. [et al.] // J. Heart Transplant. –1990 Vol. 9. – P. 627–629.
Herman E.H. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin / Herman E.H., Zhang J., Lipshultz S.E. // J. Clin. Oncol. – 1999. – Vol. 17. – P. 2237–2243.
Horino N. Elevation of lipid peroxide in children treated with a combination of chemotherapeutic agents including doxorubicin / Horino N., Kobayashi Y., Usui T. // Acta Paediatr. Scand. – 1983. – Vol. 72(4). – P. 549–551.
Human heart cytosolic reductases and anthracycline cardiotoxicity / Mordente A., Meucci E., Martorana G.E. [et al.] // IUBMB Life.– 2001. – Vol. 52. – P. 83–88.
Inducible nitric oxide synthase inhibition in cyclophosphamide induced hemorrhagic cystitis in rats / Oter S. Korkmaz A. Oztas E. [et al.] // Urol. Res. – 2004. – Vol. 32. – P. 185–189.
Jensin B.V. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin induced cardiomyopathy / Jensin B.V., Neilson S.L., Skovsgaard T. // Lancet. – 1996. – Vol. 347. – P. 297–299.
Kishi T. Prevention by coenzyme Q10 of the inhibition of adriamycin of coenzyme Q10 enzymes / Kishi T., Folkers K. //Cancer Treat. Rep. – 1976. – Vol. 60. – P. 223–228.
Late cardiac efects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood / Lipshultz S.E., Colan S.D., Gelber R.D. [et al.] // N. Engl. J. Med. – 1991. – Vol. 324. – P. 808.
Lefrak E.A. A clinicopathologic analysis of adriamycin cardiotoxicity / Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. [et al.] // Cancer. – 1973. – Vol. 32. – P. 302–314.
Lenaz L. Cardiotoxicity of adriamycin and related anthracyclines / Lenaz L., Page J.A. // Cancer Treat. Rev. – 1976. – Vol. 3. – P. 111–120.
Lou H. Cytokines are not upregulated in adriamycin induced cardiomyopathy and heart failure / Lou H., Danelisen I., Singal P.K. // J. Mol. Cell. Cardiol. – 2004. – Vol. 36. – P. 683–690.
Marrow transplanation in man following cyclophosphamide / Santos G.W., Sensenbrenner L.L., Burke P.J. [et al.] // Transplant. Proc. – 1971. – Vol. 3. – P. 400–404.
Mills B.A. Cyclophosphamide-induced cardiomyopathy: a report of two cases and review of the English literature / Mills B.A., Roberts R.W. // Cancer – 1979. – Vol. 43. – P. 2223 2226.
Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation / Pihkala J., Saarinen U.M., Lundstrom U. [et al.] // Eur. J. Cancer. – 1996. – Vol. 32. – P. 97–103.
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction / Daugaard G., Lassen U., Bie P. [et al.] // Eur. J. Heart Fail. – 2000. – Vol. 7. – P. 87–93.
Orthotopic heart transplantation: an effi cient treatment in a young boy with doxorubicin-induced cardiomyopathy / Luthy A., Furrer M., Waser M. [et al.] // J. Heart. Lung. Transplant. – 1992. – Vol. 11. – P. 815–816.
Praga C. Anthracyclineinduced cardiotoxicity and its relevance in cancer treatment / Praga C., Trave F., Petroccione A. // In: Nimmo W.S., Tucker G.T., eds, Clinical measurement in drug evaluation.– London: Wolfe Publishing Ltd. – 1991. – P. 131–142.
Prospective evaluation of doxorubicin induced cardiomyopathy resulting from post surgical adjuvant treatment of patients with soft tissue sarcomas / Dresdale A., Bonow R.,Wesley R. [et al.] // Cancer. – 1983. – Vol. 52. – P. 51–60.
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients / Meinardi M.T., van Veldhuisen D.J., Gietema J.A. [et al.] // J. Clin. Oncol. – 2004. – Vol. 19. – P. 2746–2753.
QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin’s lymphoma / Nousiainen T., Vanninen E., Rantala A. [et al.] // J. Intern. Med. – 1999. – Vol. 245(4). – P. 359–364.
Risk factors for doxorubicin-induced congestive heart failure / Von Hoff D.D., Layard M.W., Basa P. [et al.] // Ann. Intern. Med. – 1979. – Vol. 91. – P. 710–717.
Rosen G.M. Spin trapping biologically generated free radicals: correlating formation with cellular injury / Rosen G.M., Halpern H.J. // Methods Enzymol. – 1990. – Vol. 18. – P. 611–621.
Shan K. Anthracycline-induced cardiotoxicity / Shan K., Lincoff A.M., Young J.B. // Ann. Intern. Med. – 1996. – Vol. 125. – P. 47–58.
Singal P.K. Adriamycin cardiomyopathy: pathophysiology and prevention / Singal P.K., Iliskovic N., Li T. [et al.] //FASEB J. – 1997. – Vol. 11. – P. 931–936.
Singal P.K. Doxorubicin-induced cardiomyopathy / Singal P.K., Iliskovic N. // N. Engl. J. Med. – 1998. – Vol. 339. – P. 900–905.
Soker M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy / Soker M., Kervancioglu M. // Saudi Med. J. – 2005. – Vol. 26. – P. 1197–1202.
Steinherz S. Delayed cardiac toxicity from anthracycline therapy / Steinherz S., Steinhertz P. // Paediatrician. – 1991. – Vol. 18. – P. 49–52.
Takano H. Atrophic nerve fi bres in regions of reduced MIBG uptake in doxorubicin cardiomyopathy / Takano H., Ozawa H., Kobayashi I. [et al.] // J. Nucl. Med. – 1995. – Vol. 36. – P. 2060–2061.
Terpstra W. Pericardial fi brosis following busulfan treatment / Terpstra W., de Maat C.E. // Neth. J. Med. – 1989. – Vol. 35. – P. 249–252.
Tichelli A. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation / Tichelli A., Bhatia S., Socie G. // Br. J. Haematol. – 2008. – Vol. 142. – P. 11–26.
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy / Felker G.M., Thompson R.E., Hare J.M. [et al.] // N. Engl. J. Med. 2000. – Vol. 342. – P. 1077–1084.
Yaris N. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity / Yaris N., Ceviz N., Coskun T. // J. Exl. Clin. Cancer Res. – 2002. – Vol. 21. – P. 165–170.
Yong H.X. Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T prolymphocytic leukemia / Linn Y.C., Ong K.H., Tan D. // Leuk. Res. – 2012. – Vol. 36. – P. e163–e165.
Young C.W. Epirubicin, a therapeutically active doxorubicin analogue with reduced cardiotoxicity / Young C.W. // Bonadonna U. Advances in anthracycline chemotherapy: epirubicin / ed. Bonadonna U. – Milan: Masson, 1984. – Р. 183–188.
Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma / Jo J.C., Yoon D.H., Kim S. [et al.] // Korean J. Hematol. – 2012. – Vol. 47. – P. 119–125.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
